Contact us

Just a web browser. peakAcademy is browser-based with global 24/7 access, and conference mode is mobile- and touchscreen-optimized with no login required.

A CME certification submission is ongoing and currently planned for 2027.

Participants receive auto-generated certificates on completion and can log back in anytime to revisit their cases.

Yes. You can add sponsor logos, study disclaimers, and regulatory footers at the page level, and structure multi-stage courses with cohort control and timed unlock order.

Every case is scored against verified ground truth. Trainers see live completion dashboards and case-level metrics - percent correct, accuracy, sensitivity, and concordance vs. truth - all exportable as PDF or data for post-training review, remediation, or publication support.

Yes. You can supply your own dataset, or have Mindpeak source a custom dataset from a global network of reference centers. Mindpeak experts help plan the ideal setup for your training.

peakAcademy draws on Mindpeak's AI portfolio across solid tumor types and indications such as lung, breast, and gastric, covering biomarkers including PD-L1, HER2, TROP2, CLDN18.2, ER/PR, Ki-67, DLL3, among others. Contact us to discuss a specific target.

PhenoScout AI is For Research Use Only — not for use in diagnostic procedures. It is built to GxP-ready standards, with a full audit trail for every image ensuring traceable, reproducible analysis. Mindpeak is ISO 13485 (QMS) certified, GDPR-compliant and made in Germany, and also develops a separate line of CE-IVD clinical products.

PhenoScout integrates with leading imaging hardware (including the ZEISS Axioscan 7 / SlideStream workflow) and with laboratory IT systems (LIMS / IMS), from launching results in a separate viewer to embedding them directly in third-party IMS viewers.

PhenoScout is cloud-native and browser-based, accessible anywhere, anytime. An on-premise (dockerized, in-network) deployment is available for teams that require image and result data to remain within their own infrastructure upon request.

Two pre-trained mIF models — mIF-membrane (for membrane/cytoplasm markers such as HER2, CD8, panCK, CD68) and mIF-nucleus (for nuclear markers such as Ki67, FOXP3) — plus ready-to-use brightfield IHC-membrane and IHC-nucleus models. All are built on the peakFrontier foundation model and the mIF model is trained on 30+ immune and cancer biomarkers.

No. PhenoScout is a turn-key, off-the-shelf solution. Pre-trained models run on upload, so there's no pipeline to build, no algorithms to tune, and no bioinformatics queue to wait in.

PhenoScout accepts multiplex immunofluorescence (mIF) and brightfield images, including cyclic stainings of 20+ channels, and supports images from all major spatial platforms (e.g. RareCyte Orion, Akoya PhenoImager HT, Lunaphore COMET). AI analysis currently runs on the PhenoScout mIF model, with a generic brightfield (IHC) model available as an add-on; support for further modalities is already planned.

Mindpeak focuses on scalable Frontier Model AI built for real-world deployment in regulated environments. Our emphasis is on validation, reproducibility and long-term integration rather than experimental or isolated tools.

Mindpeak prioritizes diverse data curation, cross-site validation and continuous monitoring to support responsible and generalisable AI deployment across clinical environments.

‍

Mindpeak supports secure deployment models and complies with industry-standard data protection and IT security requirements

Mindpeak integrates with established digital pathology infrastructures and supports scalable deployment across laboratory networks and pharmaceutical partnerships.

No. Mindpeak software integrates into established digital pathology systems without disrupting routine clinical practice.

peakFrontier operates across multiplex immunofluorescence, immunohistochemistry and H&E, enabling consistent analysis across discovery, translational research and clinical development workflows.

Mindpeak develops applied AI solutions for digital pathology and precision medicine. Our technology strengthens reproducibility and confidence in tissue-based biomarker assessment across clinical diagnostics and pharmaceutical drug development.

peakFrontier is Mindpeak’s foundational AI architecture. It analyses digital pathology images, including multiplex immunofluorescence, immunohistochemistry and H&E, and converts complex tissue information into structured, quantitative outputs suitable for regulated clinical and research use.

Mindpeak’s peakFrontier AI architecture powers a portfolio of specialised applications designed for clinical and pharmaceutical use:

‍

• peakDiscover – Extracts tissue and cellular features to characterise the tumour microenvironment and identify biomarker signatures
• peakDeploy – Enables scalable deployment of AI tissue biomarker solutions across laboratory networks
• peakAcademy – An AI-native training platform supporting standardised, reproducible biomarker assessment
• peakPredict – A predictive AI ecosystem designed to support the analysis of tissue-based features in relation to treatment response and clinical outcomes

‍

Each solution draws from the same validated underlying architecture, ensuring consistency across discovery, development and clinical implementation.

No. Mindpeak’s AI is designed to support pathologists, not replace them. Our systems function as clinical decision support tools and act as added insurance in complex or high-volume environments. Final diagnostic responsibility remains with the clinician.

Yes. Mindpeak offers CE-IVD certified diagnostic products and operates under an ISO 13485 certified quality management system.

Depending on the product and region, Mindpeak solutions are available as research use only or as CE-IVD certified diagnostic tools. Regulatory status is clearly defined for each product.

Mindpeak solutions undergo structured validation prior to deployment and are evaluated across multiple clinical sites. Performance is continuously monitored in real-world environments to ensure reliability and reproducibility.

Mindpeak operates within regulated clinical environments and maintains a formal quality management system. Governance, documentation and post-deployment monitoring are integral to our approach to AI in healthcare.

Mindpeak’s AI supports quantitative biomarker assessment, companion diagnostic algorithm development and reproducible analysis across multi-site clinical trials. By reducing variability in tissue-based assessment, our technology strengthens confidence in patient stratification and endpoint evaluation.

Our AI applies consistent quantitative analysis across laboratories and clinical sites, helping to reduce inter-observer variability and standardise biomarker interpretation in global studies.